4/23/2012

Combining aliskiren with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers might lead to renal impairment, hypotension and hyperkalemia in patients with diabetes, the FDA said. The agency also advised patients with renal impairment to avoid such a combination.

Related Summaries